BELATIV Trademark

Trademark Overview


On Wednesday, December 21, 2011, a trademark application was filed for BELATIV with the United States Patent and Trademark Office. The USPTO has given the BELATIV trademark a serial number of 85500709. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Thursday, November 1, 2012. This trademark is owned by Glaxo Group Limited. The BELATIV trademark is filed in the Medical & Beauty Services & Agricultural Services category with the following description:

Gene and cell therapy
belativ

General Information


Serial Number85500709
Word MarkBELATIV
Filing DateWednesday, December 21, 2011
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateThursday, November 1, 2012
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesGene and cell therapy

Classification Information


International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, January 4, 2012
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameGlaxo Group Limited
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressGreenford, Middlesex UB60NN
GB

Trademark Events


Event DateEvent Description
Thursday, November 1, 2012ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Thursday, November 1, 2012ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Tuesday, March 27, 2012NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, March 27, 2012NON-FINAL ACTION E-MAILED
Tuesday, March 27, 2012NON-FINAL ACTION WRITTEN
Tuesday, March 20, 2012ASSIGNED TO EXAMINER
Wednesday, January 4, 2012NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, December 24, 2011NEW APPLICATION ENTERED IN TRAM

Related Keywords


belativ therapy cell gene